GSK Predicts Significant Restless Legs Market For Requip
This article was originally published in The Pink Sheet Daily
Executive Summary
The supplemental NDA for the Parkinson's therapy marks the first drug approval for restless legs syndrome. GSK says one in 10 adults have the condition.
You may also be interested in...
GSK 14-Hour Requip CR “Approvable,” FDA Says
The company is “committed” to working with FDA to determine the best path forward.
GSK 14-Hour Requip CR “Approvable,” FDA Says
The company is “committed” to working with FDA to determine the best path forward.
GSK/SkyePharma’s Requip XL Has Mid-December Action Date
Extended-release ropinirole uses Skye’s proprietary GeoMatrix technology to provide steady levels over 24 hours.